Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Imaging Study of 68Ga-R10602 in HR+ Breast Cancer
NCT06745804Phase 1Completed
- Sponsor
- Radionetics Oncology
- Start
- Dec 2024
- Primary completion
- May 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of 68Ga-R10602 in breast cancer (2 cohorts), sponsored by Radionetics Oncology. Primary endpoints: Incidence of adverse events at 7 days, Incidence of Serious Adverse Events at 7 days and 1 more. Started Dec 2024; status: completed.
02
Drugs
68Ga-R10602
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06745804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06745804.